Safer Medical Devices – in vitro skin sensitization testing with human relevance and high accuracy By Rose-Marie Jenvert, PhD, and Joshua Schmidt, PhD, SenzaGen Watch by clicking the image below.
About Tina Dackemark Lawesson
This author has yet to write their bio.
Meanwhile lets just say that we are proud Tina Dackemark Lawesson contributed a whooping 55 entries.
Toxicological Sciences, kfaa068, https://doi.org/10.1093/toxsci/kfaa068 Robin Gradin, Angelica Johansson, Andy Forreryd, Emil Aaltonen, Anders Jerre, Olivia Larne, Ulrika Mattson, Henrik Johansson Abstract Proactive identification and characterization of hazards attributable to chemicals are central aspects of risk assessments. Current legislations and trends in predictive toxicology advocate a transition from in vivo methods to non-animal alternatives. For skin sensitization assessment, […]
Thanks to all who attending yesterday’s GARDskin Dose-Response webinar. If you missed it, here’s a link to the recording.
Comments to the 2019 closing and 2020 update by CEO Axel Sjöblad.
The 2019 Annual Report in English is available. If you want to download it click here. To order a printed version, click here.
SenzaGen has received questions from customers and partners about how COVID-19 has affected our daily operations. We continue to monitor the development of the COVID-19 epidemic closely and recognize that this situation represents an unprecedented challenge to the daily lives of our communities across the globe. To date, we continue to offer our full range […]
Join SenzaGen’s web-based conference on “Difficult-to-test” substances and regulatory testing in place of our exhibitor hosted session at SOT 2020 Take this chance and participate in our web-based conference on the latest news about GARD™ and how customers use the assays for skin and respiratory sensitization testing. Key takeaways Insights on sensitization assessment of “difficult-to-test” […]
SenzaGen has received questions from customers and partners about how COVID-19 has affected our daily operations. We continue to monitor the development of the COVID-19 epidemic closely and recognize that this situation represents an unprecedented challenge to the daily lives of our communities across the globe. SenzaGen acts in adherence with the authorities’ guidelines in […]
Andy Forreryd1, Joshua Schmidt1, Robin Gradin1, Florence Burleson, Helge Gehrke3, Henrik Johansson1. 1SenzaGen AB, Lund, Sweden. 2Burleson Research Technologies, Morrisville, NC, USA. 3Eurofins BioPharma Product Testing Munich GmbH, Planegg, Germany. Sensitization of the respiratory tract by sensitizing chemicals may lead to severe bronchoconstriction and asthma-like symptoms with a potentially fatal outcome. However, proactive identification and […]